At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Stephan Stilgenbauer, MD, of Ulm University, Ulm, Germany, reviews the changing chronic lymphocytic leukaemia (CLL) treatment landscape and the progress of optimising new therapeutic approaches for clinical practice.
